Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

17.01 -0.29 (-1.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews
 
Via Benzinga
Unveiling 3 Analyst Insights On Arcturus Therapeutics
 
Via Benzinga
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
From Meiji Seika Pharma Co., Ltd. and ARCALIS, Inc.
Via Business Wire
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a... 
Via Benzinga
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
 
Via Benzinga
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM). 
Via Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.